DE60022903D1 - Olefinische trans-glukokinase-aktivatoren - Google Patents

Olefinische trans-glukokinase-aktivatoren

Info

Publication number
DE60022903D1
DE60022903D1 DE60022903T DE60022903T DE60022903D1 DE 60022903 D1 DE60022903 D1 DE 60022903D1 DE 60022903 T DE60022903 T DE 60022903T DE 60022903 T DE60022903 T DE 60022903T DE 60022903 D1 DE60022903 D1 DE 60022903D1
Authority
DE
Germany
Prior art keywords
olefinic
trans
glucocinase
activators
glucocinase activators
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60022903T
Other languages
English (en)
Other versions
DE60022903T2 (de
Inventor
Lea Corbett
Ramakanth Sarabu
Achyutharao Sidduri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of DE60022903D1 publication Critical patent/DE60022903D1/de
Publication of DE60022903T2 publication Critical patent/DE60022903T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/46—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylureas
    • C07C275/48—Y being a hydrogen or a carbon atom
    • C07C275/50—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE60022903T 1999-12-15 2000-12-12 Olefinische trans-glukokinase-aktivatoren Expired - Lifetime DE60022903T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17078399P 1999-12-15 1999-12-15
US170783P 1999-12-15
PCT/EP2000/012612 WO2001044216A1 (en) 1999-12-15 2000-12-12 Trans olefinic glucokinase activators

Publications (2)

Publication Number Publication Date
DE60022903D1 true DE60022903D1 (de) 2006-02-09
DE60022903T2 DE60022903T2 (de) 2006-07-06

Family

ID=22621235

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60022903T Expired - Lifetime DE60022903T2 (de) 1999-12-15 2000-12-12 Olefinische trans-glukokinase-aktivatoren

Country Status (33)

Country Link
US (1) US6353111B1 (de)
EP (1) EP1242397B1 (de)
JP (1) JP3824936B2 (de)
KR (1) KR100502032B1 (de)
CN (1) CN1185219C (de)
AR (1) AR032752A1 (de)
AT (1) ATE305461T1 (de)
AU (1) AU781029B2 (de)
CA (1) CA2392903C (de)
CO (1) CO5050295A1 (de)
CZ (1) CZ20022412A3 (de)
DE (1) DE60022903T2 (de)
DK (1) DK1242397T3 (de)
ES (1) ES2249322T3 (de)
GC (1) GC0000264A (de)
HK (1) HK1054383B (de)
HR (1) HRP20020514A2 (de)
HU (1) HUP0203753A3 (de)
IL (2) IL150083A0 (de)
JO (1) JO2180B1 (de)
MA (1) MA26855A1 (de)
MX (1) MXPA02005874A (de)
MY (1) MY125484A (de)
NO (1) NO323142B1 (de)
NZ (1) NZ518974A (de)
PE (1) PE20011022A1 (de)
PL (1) PL355815A1 (de)
RU (1) RU2245332C2 (de)
TW (1) TWI262916B (de)
UY (1) UY26483A1 (de)
WO (1) WO2001044216A1 (de)
YU (1) YU41402A (de)
ZA (1) ZA200203829B (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102300D0 (sv) * 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) * 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
RU2374236C2 (ru) 2001-12-21 2009-11-27 Ново Нордиск А/С Амидные производные в качестве активаторов gk
AU2003211052A1 (en) 2002-02-11 2003-09-04 Vertex Pharmaceuticals Incorporated Phospholipids as caspase inhibitor prodrugs
DE60328671D1 (de) 2002-03-26 2009-09-17 Banyu Pharma Co Ltd Neue aminobenzamidderivate
KR101124245B1 (ko) 2002-06-27 2012-07-02 노보 노르디스크 에이/에스 치료제로서 아릴 카르보닐 유도체
WO2004002481A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Aryl carbonyl derivatives as therapeutic agents
US7812167B2 (en) * 2002-10-03 2010-10-12 Novartis, Ag Substituted (thiazol-2-yl)-amides or sulfonamides as glucokinase activators useful in the treatment of type 2 diabetes
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
GB0226930D0 (en) * 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
MY141521A (en) 2002-12-12 2010-05-14 Hoffmann La Roche 5-substituted-six-membered heteroaromatic glucokinase activators
AU2003294376A1 (en) * 2003-01-06 2004-08-10 Eli Lilly And Company Heteroaryl compounds
WO2004072066A1 (en) * 2003-02-11 2004-08-26 Prosidion Limited Tri(cyclo) substituted amide glucokinase activator compounds
PL378117A1 (pl) * 2003-02-11 2006-03-06 Prosidion Limited Tricyklopodstawione związki amidowe
RU2386622C9 (ru) 2004-01-06 2021-04-21 Ново Нордиск А/С Гетероароматические производные мочевины и их применение в качестве активаторов глюкокиназы
CA2554310A1 (en) 2004-02-18 2005-09-01 Astrazeneca Ab Benzamide derivatives and their use as glucokinase activating agents
EP1735322B1 (de) * 2004-04-02 2011-09-14 Novartis AG Sulfonamidthiazolpyridinderivate als zur behandlung von typ-2-diabetes geeignete glucokinaseaktivatoren
EP1737870A1 (de) * 2004-04-02 2007-01-03 Novartis AG Thiazolopyridinderivate, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zur behandlung von durch glucokinase vermittelten leiden
EP1740560A1 (de) * 2004-04-21 2007-01-10 Prosidion Limited Tri(cyclo)substituierte amidverbindungen
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
JP2008502658A (ja) * 2004-06-17 2008-01-31 ノボ　ノルディスク　アクティーゼルスカブ 肝臓選択的グルコキナーゼ活性化因子の使用
CN101035767A (zh) * 2004-08-12 2007-09-12 普洛希典有限公司 被取代的苯乙酰胺及其作为葡糖激酶激活剂的用途
CA2614518A1 (en) 2005-07-08 2007-01-18 Novo-Nordisk A/S Dicycloalkyl urea glucokinase activators
CA2614746C (en) 2005-07-09 2011-05-10 Astrazeneca Ab Heteroaryl benzamide derivatives for use as glk activators in the treatment of diabetes
ES2426345T3 (es) 2005-07-20 2013-10-22 Eli Lilly And Company Compuesto unidos en posición 1-amino
JP2007063225A (ja) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
AU2006299091A1 (en) 2005-09-29 2007-04-12 Sanofi-Aventis Phenyl- and pyridinyl- 1, 2 , 4 - oxadiazolone derivatives, processes for their preparation and their use as pharmaceuticals
GT200600429A (es) * 2005-09-30 2007-04-30 Compuestos organicos
GT200600428A (es) * 2005-09-30 2007-05-21 Compuestos organicos
CA2626475A1 (en) * 2005-11-03 2007-05-10 Prosidion Limited Tricyclo substituted amides
PT1951658E (pt) 2005-11-17 2012-11-12 Lilly Co Eli Antagonistas do receptor do glucagon, preparação e utilizações terapêuticas
US20070197532A1 (en) * 2005-11-18 2007-08-23 Cao Sheldon X Glucokinase activators
JP5302012B2 (ja) 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
EA016853B1 (ru) 2006-08-24 2012-08-30 Юниверсити Оф Теннесси Рисерч Фаундейшн Замещенные ациланилиды и их применение
TW200825060A (en) 2006-10-26 2008-06-16 Astrazeneca Ab Chemical compounds
US7902248B2 (en) * 2006-12-14 2011-03-08 Hoffmann-La Roche Inc. Oxime glucokinase activators
JP5419706B2 (ja) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド グルコキナーゼアクチベーター
TW200831081A (en) 2006-12-25 2008-08-01 Kyorin Seiyaku Kk Glucokinase activator
WO2008104994A2 (en) 2007-02-28 2008-09-04 Advinus Therapeutics Private Limited 2,2,2-tri-substituted acetamide derivatives as glucokinase activators, their process and pharmaceutical application
MX2009009525A (es) * 2007-03-07 2009-09-16 Kyorin Seiyaku Kk Activador de glucocinasa.
US8173645B2 (en) * 2007-03-21 2012-05-08 Takeda San Diego, Inc. Glucokinase activators
EP2203448B1 (de) * 2007-09-21 2011-06-22 Sanofi-Aventis Phenothiazin-derivate mit doppelbindung, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TW200934772A (en) * 2008-01-15 2009-08-16 Lilly Co Eli Crystalline(R)-2-(4-cyclopropanesulphonyl-phenyl)-N-pyrazin-2-yl-3-(tetrahydropyran-4-yl)-propionamide
JP5287730B2 (ja) 2008-01-18 2013-09-11 アステラス製薬株式会社 フェニルアセトアミド誘導体
CA2722733C (en) * 2008-04-28 2016-02-23 Kyorin Pharmaceutical Co., Ltd. Cyclopentylacrylamide derivative
GEP20135783B (en) 2008-05-16 2013-03-11 Takeda California Inc Glucokinase activators
WO2010150280A1 (en) 2009-06-22 2010-12-29 Cadila Healthcare Limited Disubstituted benzamide derivatives as glucokinase (gk) activators
EP2459554B1 (de) 2009-07-31 2013-09-18 Cadila Healthcare Limited Substituierte benzamidderivate als glucokinase (gk)-aktivatoren
KR100970871B1 (ko) * 2009-11-30 2010-07-20 케이제이알디 (주) 바닥재 어셈블리 및 바닥재의 시공방법
TWI471132B (zh) 2009-12-04 2015-02-01 大正製藥股份有限公司 ２－吡啶酮化合物
CN102959076B (zh) 2010-03-31 2015-09-16 斯克里普斯研究所 重编程细胞
CN108143728A (zh) 2012-07-13 2018-06-12 Gtx公司 选择性雄激素受体调节剂在治疗乳癌中的用途
US9622992B2 (en) 2012-07-13 2017-04-18 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2 (en) 2012-07-13 2017-08-29 Gtx, Inc. Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10987334B2 (en) 2012-07-13 2021-04-27 University Of Tennessee Research Foundation Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
US9969683B2 (en) 2012-07-13 2018-05-15 Gtx, Inc. Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US10314807B2 (en) 2012-07-13 2019-06-11 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10258596B2 (en) 2012-07-13 2019-04-16 Gtx, Inc. Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
MY173812A (en) 2012-11-13 2020-02-24 Nissan Chemical Ind Ltd 2-pyridone compound
GB201714777D0 (en) 2017-09-14 2017-11-01 Univ London Queen Mary Agent
JP2021526130A (ja) 2018-06-12 2021-09-30 ブイティーブイ・セラピューティクス・エルエルシー インスリンまたはインスリン類似体と組み合わせたグルコキナーゼ活性化薬の治療的使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8909574D0 (en) 1989-04-26 1989-06-14 Ici Plc Chemical process
US5169951A (en) 1990-04-23 1992-12-08 Ciba-Geigy Corporation Process for preparing nematicidal compositions
ATE278680T1 (de) * 1999-03-29 2004-10-15 Hoffmann La Roche Glukokinase aktivatoren

Also Published As

Publication number Publication date
CA2392903C (en) 2008-08-05
HRP20020514A2 (en) 2004-06-30
IL150083A (en) 2010-04-15
CO5050295A1 (es) 2001-06-27
DE60022903T2 (de) 2006-07-06
NO20022863D0 (no) 2002-06-14
UY26483A1 (es) 2001-06-29
NZ518974A (en) 2004-04-30
HK1054383A1 (en) 2003-11-28
MXPA02005874A (es) 2002-10-23
CN1185219C (zh) 2005-01-19
MY125484A (en) 2006-08-30
KR100502032B1 (ko) 2005-07-25
CN1411453A (zh) 2003-04-16
CA2392903A1 (en) 2001-06-21
JP3824936B2 (ja) 2006-09-20
RU2245332C2 (ru) 2005-01-27
GC0000264A (en) 2006-11-01
HK1054383B (zh) 2005-04-22
CZ20022412A3 (cs) 2002-10-16
AU2365201A (en) 2001-06-25
EP1242397A1 (de) 2002-09-25
TWI262916B (en) 2006-10-01
IL150083A0 (en) 2002-12-01
YU41402A (sh) 2005-07-19
AU781029B2 (en) 2005-04-28
ES2249322T3 (es) 2006-04-01
NO20022863L (no) 2002-06-14
AR032752A1 (es) 2003-11-26
ATE305461T1 (de) 2005-10-15
NO323142B1 (no) 2007-01-08
HUP0203753A2 (hu) 2003-03-28
DK1242397T3 (da) 2006-02-13
PL355815A1 (en) 2004-05-17
US6353111B1 (en) 2002-03-05
KR20020067555A (ko) 2002-08-22
ZA200203829B (en) 2003-08-14
WO2001044216A1 (en) 2001-06-21
JO2180B1 (en) 2003-04-23
HUP0203753A3 (en) 2004-12-28
JP2003516980A (ja) 2003-05-20
PE20011022A1 (es) 2001-10-11
EP1242397B1 (de) 2005-09-28
MA26855A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
ATE305461T1 (de) Olefinische trans-glukokinase-aktivatoren
ATE278680T1 (de) Glukokinase aktivatoren
DE69912411D1 (de) Olefinpolymerisation
DE60044873D1 (de) Orientierte biopolymermembrane
DE122007000064I2 (de) Erythropoietinkonjugate
DE19983871T1 (de) Fönvorrichtung
DE60134470D1 (de) Para-amin substituierte phenylamid glukokinase activatoren
DE10084676T1 (de) Einmallanzettvorrichtung
DE50002834D1 (de) Handstempel
DK1311504T3 (da) Tetrazolyl-phenylacetamid-glucokinase-aktivatorer
DE60013454D1 (de) Wekzeugmaschine
ATE357433T1 (de) 4-pyrimidinyl-n-acyl-l-phenylanine
ATE297895T1 (de) 4-pyridinyl-n-acyl-l-phenylalanine
DE69921460D1 (de) Olefinpolymerisation
DE50000805D1 (de) Aufsitzspanner
DE10085008T1 (de) Oberflächenbehandlungsdüse
DE50003660D1 (de) Diacylhydrazinderivate
DE50003259D1 (de) Textilie
DE19983890T1 (de) Ventiltaktgebungsjustiereinrichtung
DE50001640D1 (de) Nahfeldoptische untersuchungsvorrichtung
ATE269311T1 (de) Benzoylpyridazine
DE10082008D2 (de) Ausbeulgerät
DE50003283D1 (de) Exzenterspannzwinge
ATE440824T1 (de) Nitro-sulfobenzamide
ATA107599A (de) Heizwasserbereiter

Legal Events

Date Code Title Description
8364 No opposition during term of opposition